Know Cancer

forgot password

A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma

Phase 2
18 Years
Not Enrolling
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma

Thank you

Trial Information

A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma


I. To evaluate the progression-free survival of patients with malignant pleural mesothelioma
(MPM) treated with anti-HGF monoclonal antibody AMG 102 in combination with pemetrexed
disodium and cisplatin.


I. To assess the toxicity associated with this regimen in these patients. II. To determine
the response rate of patients treated with this regimen. III. To determine the overall
survival of patients treated with this regimen. IV. To evaluate multiple potential
correlative biomarkers in MPM that are relevant to this combined regimen, including serum
HGF and mesothelin levels, c-met expression by IHC in tumor specimens, presence of c-met
mutations in tumor, and the presence of thymidylate synthetase (TS) and excision repair
cross complementing protein-1 (ERCC1) polymorphisms.

OUTLINE: This is a multicenter study.

Patients receive anti-HGF monoclonal antibody AMG 102 (AMG 102) IV over 1 hour, pemetrexed
disodium IV over 10 minutes, and cisplatin IV over 1 hour on day 1. Treatment repeats every
21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Patients without disease progression may continue AMG 102 IV over 1 hour on day 1, every 3
weeks, as maintenance therapy in the absence of disease progression. Some patients undergo
blood sample collection at baseline and periodically during study for correlative biomarker
studies. Tumor samples from diagnostic tissue may also be analyzed.

After completion of study therapy, patients are followed up periodically every 3 months for
2 years and then every 6 months for 1 year.

Inclusion Criteria:

- Histologically and cytologically confirmed malignant mesothelioma of the pleura

- All subtypes allowed

- Disease not amenable to curative surgery

- Measurable disease

- Patients with disease not measurable by standard RECIST criteria (i.e., pleural
rinds/thickening only) allowed

- Pleural effusions or positive bone scans are not considered measurable

- No prior radiotherapy to the target lesion or measurable lesion unless the site has
subsequent evidence of progression

- Patients who have undergone pleurodesis allowed

- Post-pleurodesis CT scan required

- No known or suspected brain metastases

- ECOG performance status 0-1

- ANC ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase ≤ 1.5 times ULN

- ALT and AST ≤ 1.5 times ULN

- Albumin ≥ 2.5 g/dL

- Creatinine clearance ≥ 45 mL/min OR serum creatinine ≤ 1.5 times ULN

- Able to take folic acid and vitamin B12

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must agree to use effective contraception

- No active infection or serious concomitant systemic disorder in compatible with the

- No thrombosis or vascular ischemic events within the last 12 months, including any of
the following:

- Deep venous thrombosis

- Pulmonary embolism

- Transient ischemic attack

- Cerebral infarction

- Myocardial infarction

- No peripheral edema ≥ grade 3

- No serious or non-healing wounds

- No second primary malignancy except in situ carcinoma of the cervix or breast, other
in situ malignancies, adequately treated basal cell carcinoma of the skin, or other
malignancy within the past 3 years with no evidence of recurrence

- No concurrent antiretroviral therapy for HIV-positive patients

- At least 4 weeks since prior radiotherapy

- More than 30 days since major surgery procedures or > 14 days since any minor
surgical procedure and recovered

- Central venous catheter placement, fine-needle aspiration, thoracentesis, or
paracentesis are not considered major or minor surgical procedures

- No prior systemic chemotherapy for mesothelioma

- No prior intracavity cytotoxic drugs or immunomodulators (unless for the purpose of

- No prior anti-HGF monoclonal antibody AMG 102, other c-MET, or HGF inhibitors

- No prior or concurrent anticoagulation therapy within the past 7 days

- Low-dose Coumadin-type anticoagulants or low-molecular weight heparin for
prophylaxis against central venous catheter thrombosis allowed

- No investigational agents within the past 4 weeks

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression-free survival

Outcome Time Frame:

From registration to clinical evidence of disease progression or death without progression, assessed up to 3 years

Safety Issue:


Principal Investigator

James Stevenson

Investigator Role:

Principal Investigator

Investigator Affiliation:

Eastern Cooperative Oncology Group


United States: Institutional Review Board

Study ID:




Start Date:

April 2010

Completion Date:

Related Keywords:

  • Advanced Malignant Mesothelioma
  • Epithelial Mesothelioma
  • Recurrent Malignant Mesothelioma
  • Sarcomatous Mesothelioma
  • Mesothelioma